Metastatic Prostate Cancer: Optimization of Systemic Treatment

Wednesday, 3 July 2024 | Urogenital

Clinical trials investigating various drugs in patients with metastatic hormone-sensitive or castration-resistant prostate cancer have revealed significant benefits. While research is ongoing to shed light on issues such as sequencing, treatment de-escalation and biomarkers, translating the accepted evidence into everyday clinical practice still represents a challenge.

Deborah Mukherji

Clemenceau Medical Center, Dubai

Explore More



Lung Icon

Lung Cancer

Uterus Icon

Women's Cancers

Bladder Icon


GI Icon


Hematology Icon


Other Solid Tumor Icon

Other Tumors

Related Posts

Leading Opinions

This article was produced in cooperation with our partners at Leading Opinions Hämatologie & Onkologie, published by Universimed. The original article in its original language can be found via and

To continue, please login or sign up first